Apixaban Dosing in Renal Impairment
Standard Dosing Algorithm
- The European Society of Cardiology recommends a standard dose of apixaban of 5 mg twice daily for most patients, with dose reduction to 2.5 mg twice daily required when patients meet at least 2 of 3 specific criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1
- The American Heart Association suggests that patients require dose reduction to 2.5 mg twice daily only if they meet ≥2 of the following 3 criteria: age ≥80 years 1, body weight ≤60 kg 2, or serum creatinine ≥1.5 mg/dL 2
Renal Function-Specific Guidance
- For patients with mild renal impairment (CrCl 50-79 mL/min), the standard dose of 5 mg twice daily is recommended, with no automatic dose reduction based on renal function alone 3, 4
- For patients with moderate renal impairment (CrCl 30-50 mL/min), the standard dose of 5 mg twice daily is recommended unless the patient meets ≥2 dose-reduction criteria, and apixaban is preferred over other DOACs due to its low renal clearance of 27% 1, 5
- For patients with severe renal impairment (CrCl 15-29 mL/min), the standard dose of 5 mg twice daily can be used, but dose reduction to 2.5 mg twice daily is recommended if the patient meets ≥2 dose-reduction criteria 4
Critical Dosing Pitfalls to Avoid
- The European Society of Cardiology warns against underdosing based on a single criterion rather than requiring 2 criteria, as studies show 9.4-40.4% of apixaban prescriptions involve inappropriate dose reduction 2
Monitoring Requirements
- The American Heart Association recommends annual monitoring for patients with CrCl ≥60 mL/min, every 3-6 months for patients with CrCl 30-60 mL/min, and more frequent monitoring for patients with CrCl <30 mL/min or dialysis 3, 2
Drug Interactions Requiring Dose Adjustment
- The European Medicines Agency advises avoiding or using caution with strong P-glycoprotein and CYP3A4 inhibitors, such as ketoconazole, itraconazole, and verapamil 3